Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term, Open-label Extension Study for Patients With Duchenne Muscular Dystrophy Enrolled in Clinical Trials Evaluating Casimersen or Golodirsen

NCT03532542 is registered in ClinicalTrials.gov with Sarepta Therapeutics, Inc. as lead sponsor.

NCT NCT03532542
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03532542 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term, Open-label Extension Study for Patients With Duchenne Muscular Dystrophy Enrolled in Clinical Trials Evaluating Casimersen or Golodirsen
Lead sponsor
Sarepta Therapeutics, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
August 2, 2018
Completion date
July 26, 2023
Enrollment
171 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy